What the Bill Means for Cannabis Patients
The draft legislation restricts reimbursement to extracts in standardized quality, finished pharmaceutical products, and preparations containing the active ingredients dronabinol and nabilon. Dried cannabis flower would be removed from the benefits catalog. Patients could still obtain flower through private prescription, but would bear the full cost themselves. After roughly one hour of debate, the Bundestag referred the draft to the relevant committees, with the Health Committee taking the lead.
📑 Inhaltsverzeichnis
For many patients, flower is far more than one option among several. Those familiar with the prescribed cannabis route understand how demanding dose adjustment can be. Our guide offers practical insight into how patients can obtain cannabis on prescription.
130 Million Euro in Savings and the Ministry’s Addiction Argument
The Federal Ministry of Health justifies the removal by citing increased addiction risk. When flower is inhaled, the active ingredient enters the system rapidly—a concern particularly relevant for long-term therapy. The government expects tangible financial benefits. In 2027 alone, insurers expect savings of approximately 130 million euros; by 2030, the total anticipated relief reaches roughly 625 million euros. The cannabis provision is just one small component. Overall, the bill aims to relieve statutory health insurance of 16.3 billion euros in 2027, climbing to 38.1 billion euros by 2030.
The addiction argument remains controversial. The debate surrounding consumption risks unfolds more nuanced in expert circles than a blanket justification might suggest. Our analysis of cannabis and psychosis illuminates which groups are genuinely at risk.
Why Pharmacists and Advocacy Groups Warn of Higher Costs
A broad coalition of pharmacy and patient organizations views the planned savings as economically flawed. The Association of Cannabis-Supplying Pharmacies and the German Hemp Association warn of supply cuts without genuine cost reduction. Their central argument centers on price. Measured by active ingredient content, flower is the most affordable form of cannabis medicine.
The numbers make this clear. For 1,000 milligrams of pure THC, oil-based dronabinol costs roughly 400 euros, while the finished pharmaceutical Sativex runs approximately 380 euros. Flower with 22 percent THC costs only 40 to 90 euros. If flower is eliminated, many patients will inevitably switch to costlier extracts. Expenses shift rather than disappear. There’s also a therapeutic dimension at stake. When transitioning from whole flower to isolated active compounds, the synergistic interplay of plant compounds is lost. New research on terpenes in pain medicine demonstrates the significance of this interaction.
What Happens After First Reading
With referral to the committees, substantive work truly begins. In coming weeks, hearings and possible amendments follow before the Bundestag votes in second and third reading. Afterward, the Bundesrat addresses the proposal. Until then, reimbursement for cannabis flower remains intact. Patients should avoid premature therapy changes and instead await further developments.
The planned removal joins a series of regulatory tightening measures. Recently, rules governing online prescriptions came under political scrutiny, as our piece on cannabis telemedicine under pressure shows. For many observers, a pattern emerges: medical provision is being progressively constrained.
Frequently Asked Questions
Will cannabis flower stop being covered by insurance effective immediately?
No. On June 12, 2026, only the first reading in the Bundestag took place. The draft was referred to committees and is not yet law. Reimbursement entitlement remains in effect until final passage.
Which cannabis medicines will insurers still cover?
According to the draft, extracts in standardized quality, finished pharmaceutical products, and preparations containing dronabinol and nabilon remain reimbursable. Only dried flower would be removed from the benefits catalog.
Why does the Health Ministry want to eliminate flower coverage?
The ministry cites two reasons. First, it views inhaled flower as carrying increased addiction risk due to rapid onset. Second, the measure aims to provide financial relief to insurers—approximately 130 million euros annually in 2027, according to the draft.
What do pharmacists and the Hemp Association criticize?
The organizations question the savings logic. Since flower represents the lowest-cost cannabis medicine per milligram of THC, patients would be forced to switch to costlier extracts. They argue this threatens supply without delivering anticipated savings.
What can affected patients do now?
It’s advisable to discuss the situation with your treating physician and follow the procedure’s progression. Hasty therapy changes are unnecessary at present. The advocacy groups mentioned also provide information and resources for affected patients.
Sources: Deutscher Bundestag (Parliamentary record of first reading, GKV-Beitragssatzstabilisierungsgesetz, June 12, 2026), Federal Ministry of Health, Association of Cannabis-Supplying Pharmacies (VCA), German Hemp Association (DHV).
Sollten Cannabisblüten weiter auf Kassenrezept erstattet werden?
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
